Amorphous Donepezil Hydrochloride Tablet Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The production of tablets containing donepezil hydrochloride in amorphous form is challenging due to its hygroscopicity, low bulk density, poor flow behavior, and poor physical stability, which can lead to conversion of crystalline forms and affect bioavailability and therapeutic consistency.
Innovation Solution
A process involving the use of crystalline, dehydrated donepezil hydrochloride granules, obtained through wet granulation and controlled drying, which are then compressed into tablets, resulting in an amorphous form with improved stability and bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If donepezil hydrochloride is prepared in crystalline form, then physical stability is improved, but solubility and dissolution rate deteriorate
Solution Approach 1:
The patent changes the physical state parameter of donepezil hydrochloride from crystalline to amorphous form. This parameter change simultaneously improves solubility and dissolution rate while maintaining physical stability through controlled preparation methods that prevent unwanted polymorphic transitions.
Solution Approach 2:
The patent applies preliminary action by preparing donepezil hydrochloride in amorphous form before tablet manufacturing. The amorphous material is prepared and stabilized in advance using specific preparation methods, then incorporated into tablets, ensuring consistent bioavailability without requiring crystalline forms.
2Difficulty of detecting and measuring
If donepezil hydrochloride is stored as amorphous material, then solubility and dissolution rate are improved, but physical stability deteriorates due to easy conversion between crystalline forms
Solution Approach 1:
The patent employs amorphous donepezil hydrochloride as a short-living intermediate form that is prepared, immediately processed into tablets, and then stabilized in the final pharmaceutical product. The amorphous form is not intended for long-term storage but serves as a transient state during manufacturing, eliminating the need for long-term stability of the amorphous form itself.
Solution Approach 2:
The patent utilizes parameter changes by controlling the physical state transitions of donepezil hydrochloride. The amorphous form is prepared under specific conditions, then rapidly converted into the final tablet product where stability is achieved through formulation, not through maintaining the amorphous state indefinitely.
3Manufacturing precision
If donepezil hydrochloride is processed through multiple crystallization steps, then purity is improved, but manufacturing complexity increases due to polymorphic conversions
Solution Approach 1:
The patent extracts the problematic polymorphic conversion steps from the manufacturing process by directly preparing donepezil hydrochloride in amorphous form in a single step. This eliminates the need for multiple crystallization and drying steps required to control polymorphic forms, thereby reducing manufacturing complexity while maintaining purity.
Solution Approach 2:
The patent inverts the conventional approach by preparing the active ingredient in amorphous form rather than crystalline form. This inversion simplifies the manufacturing process by eliminating the need to control and manage multiple crystalline polymorphs, reducing manufacturing complexity while achieving the required purity.
4Stability of the object's composition
If donepezil hydrochloride is stored with high water content, then physical stability is improved by preventing amorphous-to-crystalline conversion, but bioavailability deteriorates
Solution Approach 1:
The patent applies parameter changes by optimizing the water content to a specific range (3-15%) rather than using high water content. This parameter optimization achieves the dual benefit of maintaining physical stability of the amorphous form while preserving the solubility and dissolution rate necessary for good bioavailability.
Solution Approach 2:
The patent applies partial action by adding a specific amount of water (3-15%) that is sufficient to maintain amorphous stability but not excessive enough to harm bioavailability. This controlled partial hydration achieves the optimal balance between physical stability and therapeutic performance.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process produces physically stable tablets with donepezil hydrochloride in amorphous form, minimizing recrystallization and ensuring consistent therapeutic activity, with residual water content optimized for stability and bioavailability.
Implementation Method 1
the granules are obtained by wet granulation and controlled drying
Implementation Method 2
When compressing a tablet mass comprising granules, which granules contain a hydrochloride salt of donepezil in a crystalline and dehydrated form, a tablet can be obtained which in turn contains the hydrochloride salt of donepezil in an amorphous form
Data Source
AI summary
The present invention relates to a method for the production of a tablet containing the hydrochloride salt of donepezile in amorphous form, characterized in that a granulate is utilized during the compacting of a tablet mass comprising a granulate, in which a hydrochloride salt of donepezile is contained in a crystalline form. The present invention further relates to the use of a hydrochloride salt of donepezile in a crystalline form for the production of a granulate, wherein the granulate contains a hydrochloride salt of donepezile in a crystalline and dehydrated form.